Macroesis

Macroesis is a biotechnology company focused on developing first-in-class therapeutics that target macropinocytosis, a specialized nutrient-scavenging pathway. This process is frequently exploited by cancer cells, particularly those harboring RAS mutations, to internalize extracellular proteins and sustain growth within nutrient-depleted tumor microenvironments. By inhibiting this mechanism, Macroesis aims to effectively starve tumor cells, offering a novel metabolic approach to treating aggressive malignancies such as pancreatic ductal adenocarcinoma. The company's scientific foundation is based on the pioneering research of Dr. Dafna Bar-Sagi, a leading expert in cell biology and cancer metabolism. Macroesis is currently in the pre-clinical stage, advancing a pipeline of inhibitors designed to disrupt this critical survival pathway. The company operates as a spin-out from NYU Langone Health and is positioned at the intersection of oncology and metabolic reprogramming.